Table 1 Distribution of mutations of the UroSEEK gene panel in noninvasive bladder cancer
Low-grade noninvasive papillary carcinoma | High-grade noninvasive papillary carcinoma + carcinoma in situ | p-value | |||
|---|---|---|---|---|---|
UroSEEK genes | 185/188 (98%) | 161/185 (87%) | <0.0001 | ||
TERTSeqS | 145/188 (77%) | 121/185 (65%) | 0.017 | ||
UroSeqS | 131/188 (70%) | 108/185 (58%) | 0.030 | ||
FGFR3 | 87/188 (46%) | 42/185 (23%) | <0.0001 | ||
TP53 | 15/188 (8%) | 51/185 (28%) | <0.0001 | ||
PIK3CA | 35/188 (19%) | 9/185 (5%) | <0.0001 | ||
CDKN2A | 10/188 (5%) | 7/185 (4%) | 0.644 | ||
HRAS | 6/188 (3%) | 3/185 (2%) | 0.515 | ||
KRAS | 5/188 (3%) | 4/185 (2%) | 1.0 | ||
ERBB2 | 1/188 (1%) | 3/185 (2%) | 0.604 | ||
VHL | 1/188 (1%) | 3/185 (2%) | 0.604 | ||
MLL | 0/188 (0%) | 1/185 (1%) | 0.994 | ||
MET | 0/188 (0%) | 0/185 (0.0%) | . | ||
